MedPath

Dexamethasone

Generic Name
Dexamethasone
Brand Names
Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
Drug Type
Small Molecule
Chemical Formula
C22H29FO5
CAS Number
50-02-2
Unique Ingredient Identifier
7S5I7G3JQL
Background

Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication

Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions
Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
Associated Therapies
-

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

Phase 1
Terminated
Conditions
Multiple Myeloma
Plasma Cell Neoplasm
Interventions
First Posted Date
2008-11-14
Last Posted Date
2018-10-24
Lead Sponsor
PrECOG, LLC.
Target Recruit Count
63
Registration Number
NCT00790842
Locations
🇺🇸

Metro MN CCOP, Saint Louis Park, Minnesota, United States

🇺🇸

Emory University Winship Cancer, Atlanta, Georgia, United States

🇺🇸

Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States

and more 13 locations

Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect

Not Applicable
Completed
Conditions
Insulin Resistance
Glucose Intolerance
Interventions
First Posted Date
2008-11-04
Last Posted Date
2014-05-21
Lead Sponsor
University Hospital, Gentofte, Copenhagen
Target Recruit Count
21
Registration Number
NCT00784745
Locations
🇩🇰

Bispebjerg Hospital, Copenhagen, Denmark

Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
First Posted Date
2008-11-04
Last Posted Date
2016-10-07
Lead Sponsor
Mayo Clinic
Target Recruit Count
36
Registration Number
NCT00784927
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Phase 2
Completed
Conditions
Follicular Lymphoma
Marginal Zone B-Cell Lymphoma
MALT Lymphoma
Lymphoma of Mucosa-Associated Lymphoid Tissue
Lymphoma, Small Lymphocytic
Waldenstrom Macroglobulinemia
Mantle-Cell Lymphoma
Interventions
First Posted Date
2008-10-31
Last Posted Date
2023-03-30
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
50
Registration Number
NCT00783367
Locations
🇺🇸

University of Pennsylvania; Abramson Cancer Center; Lymphoma Program, Philadelphia, Pennsylvania, United States

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

Phase 2
Completed
Conditions
Choroidal Neovascularization
Age-Related Maculopathy
Interventions
Drug: dexamethasone
Biological: ranibizumab
First Posted Date
2008-10-20
Last Posted Date
2012-09-03
Lead Sponsor
Allergan
Target Recruit Count
44
Registration Number
NCT00775411

Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)

Phase 2
Completed
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
First Posted Date
2008-10-16
Last Posted Date
2021-04-01
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
143
Registration Number
NCT00773838

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
First Posted Date
2008-10-15
Last Posted Date
2020-01-18
Lead Sponsor
Mayo Clinic
Target Recruit Count
39
Registration Number
NCT00772915
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)

Phase 3
Completed
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
First Posted Date
2008-10-10
Last Posted Date
2014-10-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
103
Registration Number
NCT00770562

Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive

Phase 2
Completed
Conditions
Leukemia, Lymphocytic, Acute
Philadelphia Chromosome
Blast Crisis
Leukemia, Myeloid, Chronic
Interventions
First Posted Date
2008-10-01
Last Posted Date
2011-10-05
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
55
Registration Number
NCT00763763
Locations
🇫🇷

Service Clinique des Maladies du Sang, Paris, France

© Copyright 2025. All Rights Reserved by MedPath